Drug firm Jubilant Life Sciences has received its shareholders’ approval to raise Rs 2,000 crore through redeemable non-convertible debentures (NCDs) on a private placement basis or rights basis in one or more tranches. Additionally, the borrowing through debentures will be within the above overall borrowing limit of Rs 5,000 crore.
Jubilant Life Sciences is engaged in manufacture and supply of active pharmaceutical ingredient (APIs), solid dosage formulations, radio pharmaceuticals, allergy therapy products and life science ingredients. It also provides services in contract manufacturing of sterile injectables and ointments, creams and liquids and drug discovery and development.
